Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
Authors:
- Tae Kon KimTKTae Kon Kim
- Sarah PerreaultSPSarah Perreault
- Daniel ZeltermanDZDaniel Zelterman
- Stuart SeropianSSStuart Seropian
- 19 July 2018
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 98 (1) , 237-240
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemiaBlood, 2012
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Immunoregulatory functions of mTOR inhibitionNature Reviews Immunology, 2009
- HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantationBone Marrow Transplantation, 2006
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2005
- Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantationBlood, 2003
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986